Technology | 2009.11.04
Flamel Technologies Announces Licensing Agreement with Pfizer
LYON, France--(BUSINESS WIRE)--Flamel Technologies (Nasdaq:FLML) today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel’s Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel will receive a further payment of $1 million pursuant to the exercise of the license; Pfizer will pay all development costs of the program, including milestone payments and royalties on any worldwide commercial sal
For more information, please visit
http://www.businesswire.com/news/home/20091104005672/en
